Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

Rhea-AI Summary

Immuneering (Nasdaq: IMRX), a clinical-stage oncology company focused on universal-RAS/RAF cancer medicines, will participate in the Piper Sandler 36th Annual Healthcare Conference in New York City from December 3-5, 2024. The company's management team will present in a fireside chat format on December 5 from 1:00-1:25 pm ET, discussing their pipeline, platform, and business strategy. The presentation will be available via live webcast and archived on Immuneering's website in the Investor Relations section.

News Market Reaction – IMRX

+3.90%

+3.90% Session move

In the trading session that priced this news, IMRX gained 3.90%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will present at the Piper Sandler 36^th Annual Healthcare Conference, which is taking place at the Lotte New York Palace in New York City from December 3-5, 2024, to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Chief Executive Officer, Harold “E.B.” Brakewood, Chief Business Officer and Mallory Morales, CPA, Chief Accounting Officer, Treasurer.

Format: Fireside Chat and 1x1 Investor Meetings

Date/Time: December 5 from 1:00 pm – 1:25 pm ET

The presentations will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.

About Immuneering Corporation

Immuneering is a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy. The Company aims to achieve universal activity through Deep Cyclic Inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneering’s lead product candidate, IMM-1-104, is an oral, once-daily Deep Cyclic Inhibitor currently in a Phase 2a trial in patients with advanced solid tumors including those harboring RAS mutations. IMM-6-415 is an oral, twice-daily Deep Cyclic Inhibitor currently in a Phase 1/2a trial in patients with advanced solid tumors harboring RAS or RAF mutations. The company’s development pipeline also includes several early-stage programs. For more information, please visit www.immuneering.com.

Media Contact:
Gina Nugent
gina@nugentcommunications.com

Investor Contact:
Laurence Watts
619-916-7620
laurence@newstreetir.com

FAQ

When is Immuneering (IMRX) presenting at the Piper Sandler Healthcare Conference 2024?

Immuneering (IMRX) will present on December 5, 2024, from 1:00 PM to 1:25 PM ET at the Piper Sandler Healthcare Conference.

Where can I watch Immuneering's (IMRX) Piper Sandler Conference presentation?

The presentation will be webcast live and archived in the Investor Relations section of Immuneering's website under Events & Presentations.

What will Immuneering (IMRX) discuss at the Piper Sandler Healthcare Conference?

Immuneering will discuss their pipeline, platform, and business strategy, focusing on their development of universal-RAS/RAF medicines for cancer patients.

Where is the Piper Sandler Healthcare Conference 2024 being held?

The conference is being held at the Lotte New York Palace in New York City from December 3-5, 2024.